芪苈强心胶囊联合沙库巴曲缬沙坦对慢性心力衰竭患者心功能的影响  

Effect of Qili Qiangxin Capsule Combined with Sacubitril/Valsartan on Cardiac Function in Patients with Chronic Heart Failure

作　　者：高艳艳[1] 刘丽芳 高磊 王华萍[1] 刘恒亮 GAO Yanyan;LIU Lifang;GAO Lei;WANG Huaping;LIU Hengliang(Department of Cardiology,Shenqiu County Hospital of Traditional Chinese Medicine,Shenqiu 466300,China;Department of Cardiology,Affiliated People’s Hospital of Zhengzhou,The Second School of Clinical Medicine,Southern Medical University,Zhengzhou 450003,China)

机构地区：[1]沈丘县中医院心内科,河南沈丘466300 [2]南方医科大学第二临床医学院附属郑州人民医院心内科,郑州450003

出　　处：《中国现代应用药学》2020年第20期2516-2520,共5页Chinese Journal of Modern Applied Pharmacy

基　　金：郑州市创新型科技人才队伍建设项目(096SYJH33114)。

摘　　要：目的探讨芪苈强心胶囊联合沙库巴曲缬沙坦对慢性心力衰竭(chronic heart failure,CHF)患者心功能的影响。方法102例CHF患者随机分为沙库巴曲缬沙坦组(对照组)和芪苈强心胶囊联合沙库巴曲缬沙坦组(观察组),分别给予沙库巴曲缬沙坦和沙库巴曲缬沙坦联合芪苈强心胶囊口服治疗6个月,观察患者显效率、有效率和左室舒张末期内径(left ventricular end-diastolic diameter,LVEDD)、左心门室收缩末期内径(left ventricular end-systolic diameter,LVESD)、左心室射血分数(left ventricular ejection fraction,LVEF)、心输出量(cardiac output,CO),NYHA II级的改善率、血氨基末端B型脑钠肽前体(N-terminalpro-brain natriuretic peptide,NT-proBNP)、6 min步行试验(6-min walk test,6-MWT)的变化。结果2组患者治疗6个月后LVESD、LVEDD均显著低于治疗前(P<0.05),LVEF、CO均显著高于治疗前(P<0.05),但2组患者治疗6个月后LVEF和CO组间比较无显著性;观察组显效率和治疗后NHYA II级显著高于对照组(P<0.05)。2组治疗后8周、12周NT-proBNP均显著低于治疗前(P<0.05),6-MWT距离显著高于治疗前(P<0.05),但组间对比无显著性差异;观察组治疗6个月后NT-proBNP显著低于对照组(P<0.05),6-MWT距离显著高于对照组(P<0.05)。结论沙库巴曲缬沙坦联合芪苈强心胶囊能够进一步提高CHF患者NYHA分级和6-MWT距离。OBJECTIVE To investigate the effect of Qili Qiangxin capsule combined with sacubitril/valsartan on cardiac function in patients with chronic heart failure(CHF).METHODS One hundred and two patients with CHF were randomly divided into two groups:sacubitril/valsartan group(control group)and Qili Qiangxin capsule combined with sacubitril/valsartan group(observation group).Sacubitril/valsartan and sacubitril/valsartan combined with Qili Qiangxin capsule were given to the patients for six months respectively.The apparent efficiency,effective rate and left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),cardiac output(CO),NYHA II improvement rate,N-terminalpro-brain natriuretic peptide(NT-proBNP)and changes of 6-min walk test(6-MWT)were observed.RESULTS After 6 months of treatment,LVESD and LVEDD in both groups were significantly lower than those before treatment(P<0.05),LVEF and CO were significantly higher than those before treatment(P<0.05),but after 6 months of treatment,there was no significant difference between the two group.The significant efficiency and NHYA II level in observation group were significantly higher than those in control group(P<0.05).NT-proBNP in 8 and 12 weeks after treatment was significantly lower than that before treatment(P<0.05).6-MWT distance was significantly higher than that before treatment(P<0.05),there was no significant difference between the two groups.NT-proBNP in 6 months after treatment was significantly lower than that in the control group(P<0.05),and 6-MWT distance was significantly higher than that in the control group(P<0.05).CONCLUSION Sacubitril/valsartan combined with Qili Qiangxin capsule can further improve the NYHA classification and 6-MWT distance of CHF patients.

关 键 词：慢性心力衰竭 沙库巴曲缬沙坦 芪苈强心胶囊 心功能 6 min步行试验 

分 类 号：R969.4[医药卫生—药理学]